1. The Situation
The board asks why growth has stalled. Leadership runs an analysis. The pipeline is thin, win rates are declining, average deal size is flat. Obvious conclusion: we need more pipeline, better salespeople, and bigger deals.
So the company hires more SDRs, raises the bar on AE hiring, and launches an upmarket initiative. Six months later, all three investments are underperforming. The pipeline is bigger but quality is worse. The new AEs are struggling because the motion isn't documented well enough to replicate. The enterprise deals are stalling because the product has gaps at that size.
The original problem is now larger, and three new problems have been added.
2. The Usual Explanation
The mistake wasn't the investment decisions — it was the diagnosis that drove them.
When you look at symptoms and jump directly to solutions, you skip the most important step: understanding the causal mechanism. Why is the pipeline thin? Why are win rates declining? Why isn't deal size growing?
If you don't answer those questions first, you're treating the thermometer reading, not the illness.
3. Why That Fails
There are two reasons organisations consistently skip diagnosis.
First, solutions are visible and feel like action. Hiring is something you can announce. A new tool rollout has a launch date. Diagnosis is invisible — it looks like nothing is happening while it's happening.
Second, the presenting symptoms in GTM almost always map to familiar solutions. Thin pipeline → more pipeline generation. Low win rates → sales training. These mappings feel obvious, so the question "but why?" rarely gets asked.
The result is an organisation perpetually busy but not improving. Each new initiative adds complexity without resolving the underlying constraint.
4. The Actual Constraint
In any GTM system, there's one thing that, if fixed, would unlock everything else. It might be ICP clarity. It might be how deals are being qualified. It might be a gap between what marketing promises and what sales can deliver. It might be churn at a predictable point in the customer lifecycle.
The problem is that this constraint is rarely obvious from the surface metrics. You have to look at the system as a whole — how each part connects — before you can see where the real blockage is.
5. Consequences
The cost of misdiagnosis compounds in a specific way: the first investment doesn't work, so a second is made to compensate. The second creates dependencies that make the first harder to unwind. A third initiative addresses the new complexity. By the time the diagnosis is corrected, the unwinding itself becomes a major project.
The cost is not just cash — it's the 12–18 months of competitive time that was lost.
6. What Must Change
Before the next initiative is launched, run the diagnosis. Look at the system as a whole: where are deals being lost and why? What do your best customers have in common that your worst don't? Where does the sales motion break down consistently?
The answers will point to one or two leverage points. Those are the things worth fixing. Everything else is noise until those are resolved.
A good diagnostic takes 10 to 14 days. It costs less than one bad hire. And it tells you, with specificity, where to point the resources you already have.
7. How GTM-360 Thinks About This
We're not against investment, hiring, or new initiatives. We're against doing those things before you know what's actually broken.
The organisations making the most progress aren't necessarily spending more — they're spending on the right constraint. If your last two or three GTM initiatives haven't moved the needle the way you expected, it's worth asking whether the diagnosis was right before designing the next one.